Introduction {#Sec1}
============

The management of patients with adenocarcinoma of the rectum has changed over the past two decades, and though new approaches such as total neoadjuvant therapy (TNT) are being studied, the current standard for locally advanced rectal cancers is neoadjuvant long-course radiation plus chemotherapy, followed by total mesorectal excision (TME). National guidelines from the National Comprehensive Cancer Network (NCCN) and the American Society of Colon and Rectum Surgeons recommend that TME surgery should be followed by adjuvant systemic chemotherapy.[@CR1],[@CR2] One population of interest is patients who achieve a pathologic complete response (pCR) after neoadjuvant therapy. Pathologic complete response rates following neoadjuvant chemoradiation vary in the literature, from around 15--20% up to 38% in a recent randomized controlled trial.[@CR3],[@CR4] Two phase III trials were unable to identify a significant difference in disease-free (DFS) or overall survival (OS) with the addition of adjuvant chemotherapy in locally advanced rectal cancer. However, both of these studies were closed early due to poor accrual and were not focused on patients with pCR.[@CR5],[@CR6] Though there is some controversy as to whether these patients should be followed with a "watch and wait" strategy, most would currently recommend an oncologic resection in the setting of an apparent clinical complete response (cCR).[@CR7],[@CR8] The decision as to whether to administer adjuvant chemotherapy to these patients remains controversial. Two retrospective studies utilizing the National Cancer Database (NCDB), from 2006 to 2011, demonstrated a survival benefit with adjuvant chemotherapy in the setting of pCR.[@CR9],[@CR10]

Given these discrepant findings, we used a contemporary cohort of the NCDB to evaluate outcomes in patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiation followed by oncologic resection with a pCR. We hypothesized that there would be poor national compliance with the use of adjuvant chemotherapy in this subset of patients. We also hypothesized that patients who underwent adjuvant chemotherapy would demonstrate a survival advantage.

Materials and Methods {#Sec2}
=====================

Data Source {#Sec3}
-----------

The NCDB is an oncology database that consists of patient data from Commission on Cancer-accredited hospitals. The data represents over 34 million historical records and captures more than 70% of newly diagnosed cancer cases. This data includes patient demographics, facility characteristics, cancer-specific variables, surgical variables, and survival outcomes.[@CR1] This study was approved by the University of Cincinnati Institutional Review Board (IRB \#2019-0179).

Patient Cohort {#Sec4}
--------------

The NCDB Participant User File (PUF) was queried for all patients with a diagnosis of clinical T3-4 rectal adenocarcinoma and no evidence of metastatic disease from 2006 to 2015 (*n* = 70,891) (Fig. [1](#Fig1){ref-type="fig"}). We subsequently excluded patients who did not undergo neoadjuvant chemoradiation and curative resection, who died within the first 90 days after surgery, or who did not receive 40 to 70.2 Gy of radiation. We then identified only patients who had a pCR on final pathology (*n* = 2421). These patients were then divided into groups based on whether they received adjuvant chemotherapy.Fig. 1Consort diagram demonstrating inclusion and exclusion criteria to get the study cohort

Study Variables {#Sec5}
---------------

The following data was collected for all patients who met inclusion criteria: age, race, insurance status, education level (percentage of people who did not graduate from high school in the patient's zip code), income (median income in the patient's zip code), distance traveled for cancer care, facility type (academic \> 500 new cancer diagnoses annually, at least four postgraduate training programs; comprehensive community \> 500 new cancer diagnoses annually, postgraduate training optional; community 100--500 new cancer diagnoses annually, postgraduate training optional, integrated network cancer program; no minimum caseload requirement, postgraduate training optional), and Charlson-Deyo score.[@CR11],[@CR12] TNT was defined as any patient that received radiotherapy and multi-agent chemotherapy prior to oncologic resection, RT was started a minimum of 2 months after chemotherapy, and no adjuvant chemotherapy was given.[@CR13] Cancer-specific and treatment-specific variables were also collected. Hospital volume was determined by calculating the total number of surgical cases in the rectum NCDB PUF for each facility. Facilities were then divided into the top third (high volume), middle third (medium volume), and lower third (low volume).

Statistical Analysis {#Sec6}
--------------------

All variables are represented as median (interquartile range) or percentage. Variables were compared by Pearson's chi-square test or Wilcoxon rank-sum test. Kaplan-Meier and Cox proportional hazards regression analyses were used to determine the association with OS. We utilized empirical Bayes techniques to perform reliability adjustment in order to account for differences across hospitals in use of adjuvant therapy due to chance alone. This technique is used to filter out statistical noise, particularly from hospitals which have lower numbers of cases and uses the reliability of the measurement to adjust the observed rate closer to the mean.[@CR14]--[@CR17] Stepwise logistic regression was used to identify patient, cancer, and hospital-specific factors associated with the administration of adjuvant chemotherapy. Hierarchical logistic regression models were created using the "meqrlogit" command to model variation. Post-estimation commands were utilized to create empirical Bayes estimates for each hospital's random effect. This random effect was then added to the average patient risk of receiving adjuvant chemotherapy. The inverse logit analysis was performed to calculate risk and reliability-adjusted adjuvant chemotherapy use for each hospital. Individual hospitals were then ranked based on adjuvant chemotherapy use. The top and bottom 10% of hospitals were defined as high utilization hospitals (HUH) and low utilization hospitals (LUH), respectively. A *p* value of less than 0.05 was considered statistically significant. All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC) and Stata 13.1 (College Station, TX).

Results {#Sec7}
=======

Demographic and clinicopathologic differences between pCR patients who did and did not receive adjuvant chemotherapy were seen (Table [1](#Tab1){ref-type="table"}). Patients who had adjuvant chemotherapy were more likely to be young, Caucasian women. This group also consisted of a higher proportion of privately insured patients from better educated areas that were more likely to be treated at high volume, academic centers. They also had a greater median number of lymph nodes examined and higher proportion of positive nodal disease on the initial staging before neoadjuvant therapy. There were no differences in Charlson Comorbidity score, facility type, income, distance traveled, tumor grade or size, lymphovascular invasion, unplanned readmission within 30 days, or surgical procedure between groups. The use of adjuvant chemotherapy in this population has seen an upward trend over the past decade. However, adjuvant chemotherapy is still omitted in approximately two-thirds of patients (Fig. [2](#Fig2){ref-type="fig"}).Table 1Demographics of patients receiving adjuvant chemotherapy and those who did notAdjuvant chemotherapyNo adjuvant chemotherapy*p* valuePatient demographics  Age58 (50--66)62 (53--71)\< 0.01  Sex\< 0.01    Male425 (56.9%)997 (63.1%)    Female322 (43.1%)584 (36.9%)  Race\< 0.05    White660 (88.6%)1358 (86.1%)    Black40 (5.4%)130 (8.2%)    Other45 (6.0%)90 (5.7%)  Insurance status\< 0.01    Not insured27 (3.6%)48 (3.1%)    Private insurance456 (61.5%)768 (49.1%)    Medicaid50 (6.7%)90 (5.8%)    Medicare206 (27.8%)630 (40.3%)    Other government3 (0.4%)28 (1.8%)  Education\< 0.01    ≥ 21%87 (11.7%)265 (16.8%)    13--20.9%179 (24.0%)405 (25.7%)    7--12.9%249 (33.4%)500 (31.7%)    \< 7%230 (30.9%)407 (25.8%)  Facility type0.19    Community cancer program28 (3.9%)70 (4.6%)    Comprehensive community cancer program273 (38.3%)583 (38.5%)    Academic program316 (44.4%)617 (40.7%)    Integrated network cancer program95 (13.3%)246 (16.2%)  Hospital volume\< 0.01    Low25 (3.4%)63 (4.0%)    Medium104 (13.9%)303 (19.2%)    High618 (82.7%)1215 (76.9%)Cancer-related characteristics  \# of lymph nodes examined14 (10--18)13 (9--17)\< 0.01  Clinical T stage0.36    3744 (95.6%)1557 (94.8%)    434 (4.4%)86 (5.2%)  Clinical N stage\< 0.01    0353 (45.5%)880 (54.0%)    1366 (47.2%)640 (39.3%)    257 (7.4%)109 (6.7%)  Clinical T and N stage\< 0.01    T3N0344 (44.3%)845 (51.9%)    T3N1343 (44.2%)607 (37.3%)    T3N255 (7.1%)92 (5.7%)    T4N09 (1.2%)35 (2.2%)    T4N123 (3.0%)33 (2.0%)    T4N22 (0.3%)17 (1.0%)Treatment characteristics  Days from diagnosis to definitive surgical procedure133 (119--147)139 (123--160)\< 0.01  Surgical procedure0.30    Partial proctectomy, NOS507 (67.9%)1041 (65.8%)    Pull through with sphincter preservation70 (9.4%)127 (8.0%)    Total proctectomy147 (19.7%)352 (22.3%)    Total proctocolectomy, NOS15 (2.0%)28 (1.8%)    Proctectomy or proctocolectomy with resection of other organs5 (0.7%)20 (1.3%)    Proctectomy, NOS3 (0.4%)13 (0.8%)  Hospital length of stay5 (4--7)6 (4--8)\< 0.01  Days from diagnosis to radiation34 (26--45)36 (27--49)\< 0.01  Radiation dose (cGy)4500 (4500--4500)4500 (4500--4680)0.03  Days of radiation treatment39 (38--42)40 (38--43)\< 0.01  Days from diagnosis to chemotherapy34 (24--45)35 (26--48)0.06Income, distance traveled, Charlson-Deyo score, tumor grade and size, lymphovascular invasion, readmission within 30 days, and type of radiation were analyzed but not different between groupsFig. 2Adjuvant chemotherapy use by year during the study period

We next analyzed adjuvant chemotherapy outcomes and predictors of survival. The median follow-up for the entire cohort was 42.3 months and was similar in patients that did or did not receive adjuvant chemotherapy (42.7 vs. 42.0 months, *p* = 0.63, respectively). Kaplan-Meier survival analysis showed a significant survival benefit with the use of adjuvant chemotherapy (5-year OS 92 vs. 85%, *p* \< 0.01) (Fig. [3](#Fig3){ref-type="fig"}). Cox proportional regression univariate analysis found that female gender and adjuvant chemotherapy were associated with a protective effect. Older age, Medicaid insurance type, higher Charlson-Deyo score, and initial clinical stage T4 were associated with worse OS. In multivariate analysis, female gender and adjuvant chemotherapy remained associated with improved OS. Older age, higher Charlson-Deyo score, and clinical stage T4 were predictive of worse OS (Table [2](#Tab2){ref-type="table"}).Fig. 3Kaplan-Meier survival analysis demonstrated a significant survival benefit with the use of adjuvant chemotherapy (5-year survival 92 vs. 85%, *p* \< 0.01)Table 2Univariate and multivariate Cox proportional hazards survival analysisUnivariateMultivariateVariableHazard ratio (95% CI)*p* valueHazard ratio (95% CI)*p* valueAge1.05 (1.04--1.06)\< 0.011.04 (1.02--1.05)\< 0.01Female gender0.63 (0.49--0.82)\< 0.010.66 (0.51--0.86)\< 0.01Insurance type  Private insuranceRef\-\--Ref\-\--  Medicare1.13 (0.67--1.93)0.641.10 (0.65--1.88)0.72  Medicaid2.68 (2.08--3.47)\< 0.011.22 (0.87--1.74)0.25  Other government insurance2.57 (0.94--7.00)0.072.10 (0.77--5.75)0.15Hospital volume  High volumeRef\-\--Ref\-\--  Medium volume1.28 (0.95--1.72)0.101.05 (0.78--1.41)0.75  Low volume1.60 (0.89--2.86)0.121.55 (0.84--2.85)0.16Charlson-Deyo Score  0Ref\-\--Ref\-\--  11.59 (1.20--2.11)\< 0.011.40 (1.05--1.87)0.02  22.17 (1.30--3.62)\< 0.011.58 (0.94--2.67)0.08  3+4.04 (2.30--7.11)\< 0.012.85 (1.60--5.07)\< 0.01Initial clinical stage T43.27 (1.83--5.86)\< 0.012.63 (1.44--4.79)\< 0.01Adjuvant chemotherapy0.47 (0.35--0.64)\< 0.010.60 (0.44--0.82)\< 0.01Race, education level, income, tumor grade, clinical nodal stage, lymphovascular invasion, type of surgical procedure, distance of travel, radiation dose, and time from diagnosis to starting chemotherapy/radiation were not included in the model due to *p* value \> 0.05

Finally, we sought to delineate adjuvant chemotherapy utilization patterns among U.S. institutions. The median overall risk and reliability-adjusted adjuvant chemotherapy rate among hospitals was 32% (Fig. [4](#Fig4){ref-type="fig"}). Even at the highest utilization hospitals, the risk-adjusted rate of adjuvant chemotherapy only approached 60%. Patients treated at HUH were more likely to have a high school degree. HUH were more likely to be located in the Midwest and West compared with LUH. HUH consisted of a greater proportion of academic centers and lower proportion of integrated network cancer programs. Compared with patients treated at LUH, those treated at HUH were more likely to be uninsured and better educated (*p* \< 0.05 each) (Fig. [5a--d](#Fig5){ref-type="fig"}). There were no differences in hospital surgical volume or patient income between HUH and LUH.Fig. 4The median overall risk-adjusted adjuvant chemotherapy rate among hospitals was 32% that is depicted by the dashed lineFig. 5**a** Patients treated at high-utilization hospitals were more likely to be better educated as depicted by the lower proportion of patients without a high school degree. **b** Higher-utilization hospitals were more likely to be located in the Midwest and West compared with low-utilization hospitals. **c** High-utilization hospitals consisted of a greater proportion of academic centers and lower proportion of integrated network cancer programs. **d** Compared with patients treated at low-utilization hospitals, those treated at high-utilizer hospitals were more likely to be uninsured

Discussion {#Sec8}
==========

In this study, we utilized the NCDB to evaluate the use of adjuvant chemotherapy in patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiation and oncologic resection with a pCR. We found significantly improved overall survival in pCR patients who received adjuvant chemotherapy. However, 68% of all patients with pCR did not actually receive adjuvant chemotherapy, despite consensus guidelines. Hospitals that were high utilizers of adjuvant chemotherapy were more likely to be academic centers.

Similar to our study, other retrospective, propensity-matched studies utilizing the NCDB have demonstrated improved overall survival in patients who underwent adjuvant chemotherapy following a pCR.[@CR18],[@CR19] Polanco et al. showed a 5-year OS near 95% in the patients who received adjuvant chemotherapy compared with 88% in the patients who did not (*p* \< 0.01). In subgroup analysis, patients with T3 or T4 tumors and those with positive nodal disease prior to treatment received the greatest benefit from adjuvant chemotherapy.[@CR19] In contrast to these studies, a randomized controlled trial by the Dutch Colorectal Cancer Group failed to show a benefit of adjuvant chemotherapy in patients with locally advanced rectal cancer. The 5-year OS was 79.2% in the observation group and 80.4% in the adjuvant chemotherapy group. However, the study closed prior to its planned accrual and was likely underpowered to detect a difference between the groups. They also did not specifically examine patients with larger tumors or pCR following neoadjuvant chemoradiation and resection.[@CR6] In a recently published retrospective study, Voss et al. identified over 800 patients who were diagnosed with stage 2 or 3 rectal cancer and underwent neoadjuvant chemoradiotherapy followed by total mesorectal excision at 15 centers in California. They were unable to demonstrate a benefit in recurrence free survival, their primary outcome, with the use of adjuvant chemotherapy. However, similar to the trials previously discussed, this study was not powered to examine patients with pCR.[@CR20] In a Cochrane review that evaluated the use of adjuvant chemotherapy in rectal cancer in 21 eligible trials, the authors demonstrated improved survival in those receiving adjuvant chemotherapy. However, only two trials included neoadjuvant therapy, and they did not specifically look at utilization in locally advanced disease or pCR patients.[@CR21] The currently ongoing Chinese ACRNaCT trial is comparing observation with adjuvant 5-fluorouracil alone in patients with a pCR. Hopefully, this trial will add to the growing body of literature describing whether adjuvant chemotherapy offers a survival advantage beyond neoadjuvant chemoradiation and oncologic resection alone for pCR patients.[@CR22]

Given that at least some evidence from population studies shows a benefit, NCCN guidelines currently recommend adjuvant chemotherapy for all patients with stage II or III rectal cancer after neoadjuvant chemoradiation and TME.[@CR23] However, our study demonstrates a slow trend of increased adjuvant chemotherapy use, but the compliance rate remains an alarming 36% in 2015, suggesting that U.S. practice patterns deviate greatly from published recommendations. Similarly, a previous NCDB study by Xu et al. demonstrated an adjuvant chemotherapy rate of 19% in all patients with stage II or III rectal cancer, regardless of final pathology. The authors also showed that patients with pCR benefitted from adjuvant therapy, perhaps even more than patients without pCR.[@CR10] Our study, distinct from prior literature, spans a more contemporary time period, captures a more diverse picture of current management, and is the first to identify a trend to forgo adjuvant chemotherapy in patients with pCR.

In an effort to understand the immense national variability in practice patterns, we identified the top and bottom 10% of hospitals based on adjusted adjuvant chemotherapy use. Previous studies have shown that community and comprehensive treatment centers were more likely to give both neoadjuvant and adjuvant chemotherapy to stage II or III rectal cancer.[@CR10],[@CR24] Our study, on the other hand, did not show any difference in adjuvant chemotherapy use based on facility type. However, when adjusted, HUH were more likely to be academic centers and comprehensive community cancer programs. High-volume hospitals have also been shown to be associated with increased compliance with consensus guidelines.[@CR10],[@CR24] While we found that adjuvant chemotherapy was more commonly used in high-volume centers, we did not find any difference in surgical volume between HUH and LUH. Different definitions of high- and low-volume hospitals and changes in hospital classifications may account for these discordant findings. This data may suggest that higher volume, academic hospitals are more likely to follow consensus guidelines, but the question remains as to why there is such wide variability nationally. The use of multidisciplinary tumor boards may be more prevalent in high volume, academic centers. However, the NCDB does not contain this information and we are unfortunately unable to investigate that hypothesis. Patients forgo adjuvant chemotherapy for many reasons, including post-operative complications, comorbidities, patient preference, or physician recommendation. The NCDB is missing detailed information in regard to these variables and limits our ability to ascertain why these patients did not receive adjuvant chemotherapy. However, we did not find any difference in Charlson Comorbidity score between the groups. Hospital length of stay and unplanned readmission are the only surrogates available for complications. There was no difference in readmission rate and the slightly longer length of stay that is unlikely to be clinically significant. There is an entire field of knowledge transfer that seeks to identify barriers to the dissemination of information in healthcare, and it is estimated that it takes 17 years for information to translate to the bedside.[@CR25],[@CR26] Future studies should focus on identifying interventions to help disseminate evidence, identifying barriers to receiving adjuvant chemotherapy and improve outcomes for rectal cancer patients.

This study has several limitations. First, there are inherent biases to retrospective studies, but we have attempted to account for these through the use of multivariate and risk-adjusted models. Second, the NCDB is a national database and may be prone to missing or inaccurate data similar to any other large registry. The outcomes provided in the database only allow us to calculate OS and do not contain any information regarding the cause of death. The NCDB also has limited information regarding clinical decision-making and does not allow for conclusions about why there is poor compliance with adjuvant chemotherapy. The NCDB also does not contain variables such as type of chemotherapy and pathologic factors, including mesorectal fascia involvement and extramural vascular invasion, that could be associated with outcomes. Despite these shortcomings, the NCDB consists of the majority of new U.S. cancer diagnoses and contains many cancer-related variables that are not found in other large databases. There is also a growing interest in using the TNT approach, where all chemotherapy and radiation are given before surgery. This approach may improve compliance, as chemotherapy is delivered upfront, but long-term results are not yet available.[@CR27]--[@CR29] The NCDB does not delineate TNT in the database, and using the definition as described by Zhu et al., our study contains only 49 (2.0%) patients that may have undergone TNT.[@CR13] Due to the low percentage and need for a surrogate definition, these patients were not removed from the cohort.

In conclusion, adjuvant chemotherapy is associated with a survival benefit in rectal cancer patients with large initial tumors and a pCR following neoadjuvant chemoradiation and oncologic resection. However, the utilization of this strategy at U.S. hospitals is currently quite low. There is significant variability in U.S. practice patterns, with the majority of higher utilizing hospitals being academic centers. Large-scale efforts are needed to standardize treatment patterns according to national guidelines.
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